Despite delays due to travel restrictions for inspections by the Food and Drug administration, the agency is still approving drugs unrelated to the COVID-19 pandemic after virtual review of manufacturing documents.
In this video from Motley Fool Live recorded on Nov. 30, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com contributor Brian Orelli discuss the authorizations of Alnylam Pharmaceuticals ' (NASDAQ: ALNY) Oxlumo and Regeneron Pharmaceuticals ' (NASDAQ: REGN) COVID-19 antibody cocktail components casirivimab and imdevimab.
For further details see:
Is The FDA Still Approving Drugs During the Pandemic?